Safia Chatur, MD: Sacubitril/Valsartan Offers Benefit in HFrEF Across New KDIGO Risk Classes

Safia Chatur, MD, discusses the results of a PARADIGM-HF analysis at ACC.24 examining the effects of ARNI use across the updated 2024 KDIGO Risk Classifications.

Related Keywords

Massachusetts ,United States ,Safia Chatur ,Coll Cardiol ,Work Group ,American College Of Cardiology ,American College ,Annual Scientific Sessions ,Disease Improving Global Outcomes ,Massachusetts General Hospital ,Hazard Ratio ,Confidence Interval ,Valsartan Across ,Renal Impairment ,Patients With Heart ,Improving Global Outcomes ,Practice Guideline ,Chronic Kidney ,